Patents by Inventor Jean-Daniel Lelievre

Jean-Daniel Lelievre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV)
    Patent number: 10548980
    Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 4, 2020
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université Paris-Est Créteil Val de Marne, Assistance Publique-Hôpitaux de Paris (APHP)
    Inventors: Yves Levy, Jean-Daniel Lelievre, Inna Menkova-Garnier
  • P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
    Publication number: 20190022223
    Abstract: The present invention relates to pharmaceutical composition and uses thereof for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV). In particular, the present invention relates to a P2X7 receptor antagonist for use in a method of restoring T-cell lymphopoiesis in a subject infected with human immunodeficiency virus (HIV) comprising administering to the subject a therapeutically effective amount of said P2X7 receptor antagonist.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Yves LEVY, Jean-Daniel LELIEVRE, Inna MENKOVA-GARNIER
  • Soluble ST2 as a marker for risk of mortality in HIV-infected subjects
    Patent number: 9804172
    Abstract: The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: October 31, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Yves Levy, Sophie Hue, Jean-Daniel Lelievre